Study ID: TV48574-AS-20031 | 2020-001927-15
- A Study to Test if TEV-48574 is Effective in Relieving Asthma
- TV48574-AS-20031 | 2020-001927-15
- Drug: TEV-48574 | Drug: Placebo
The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).
The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.
The duration of patient participation in the study is planned to be up to approximately 30 weeks.
Key Participation Requirements
- Female, Male
- 18 Years and older
- August 25, 2020 - January 17, 2022
- Phase 2